Skador av hasch och marijuana - Statens folkhälsoinstitut

Referenser
Inledning
Lundqvist T, Ericsson D. Vägen ut ur haschmissbruket. Lund: Studentlitteratur; 1988.
Petrell B, Blomqvist J, Lundqvist T. Ut ur dimman, FoU-raport 2005:19. Stadsledningskontoret
105 35 Stockholm
Kapitel 1–2
Ashton CH, Adverse effects of cannabis and cannabinoids. Br J Anaesth 1999;83: 637-49
Ashton CH. Pharmacology and effects of cannabis: a brief review. Br J Psychiatry
2001;178:101-6.
Ashton CH, Moore PB, Gallagher P, Young AH. Cannabinoids in bipolar affective disorder:
a review and discussion of there therapeutic potential. J Psychopharmacology 2005, 19;
293
CAN (Centralförbundet för alkohol- och narkotikaupplysning ). CAN:s rapporteringssystem
om droger. Tendenser under våren 2003. Rapport nr 73. CAN/Siv Byqvist; 2003.
CAN. Drogutvecklingen i Sverige. Rapport nr 71. CAN; 2003.
Castle DJ, Ames FR. Cannabis and the brain. Aust N Z Journal P 1996; Apr 30:179-83.
Dennis M, Babor TF, Roebuck MC, Donaldson J. Changing the focus: the case for recognizing
and treating cannabis use disorders. Addiction 2002;97(suppl 1):4-15.
Fabrício MA, Lutz B. The endocannabinoid system: emotion, learning and addiction. Addiction
Biology, 13, 196 - 212
Ghodse AH. Cannabis psychosis. British J Addiction 1986;81:473-8.
Gold MS. Marijuana. New York: Plenum Medical Book Company; 1989.
Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet
2003;42(4):327-60.
Hall W, Solowij N, Lemon J. The health and psychological consequences of cannabis use.
Canberra: Australian Government Publishing Service; 1994.
112 s k a d o r av h a s c h o c h m a r i J u a n a